Machine learning algorithms can help clinicians understand risk factors for posttraumatic stress disorder (PTSD) and match them to appropriate individualized treatments, according to Isaac Galatzer-Levy, PhD, assistant professor in psychiatry and bioinformatics, NYU School of Medicine, and vice president of clinical and computational neuroscience, AiCure.
Machine learning algorithms can help clinicians understand risk factors for posttraumatic stress disorder (PTSD) and match them to appropriate individualized treatments, according to Isaac Galatzer-Levy, PhD, assistant professor in psychiatry and bioinformatics, NYU School of Medicine, and vice president of clinical and computational neuroscience, AiCure.
Transcript
How can machine learning help forecast the course and trajectory of PTSD or depression?
The causes of PTSD and depression are very heterogeneous, vary between individuals, so you need an algorithm that’s able to accommodate a lot of information and really fit what we call an individualized predictive model. So we need to be able to take in a lot of information to understand what are the unique risk factors that lead to varied outcomes. If we do take that kind of approach, we can then start to match treatments to those risk factors to have a really individualized treatment model for the prevention of posttraumatic stress responses.
Why is it important to accurately predict PTSD in the immediate aftermath of a traumatic event?
It’s very important because the vast majority of people, even in the first world, will be exposed to a life-threatening event across their life course. The epidemiological literature showed roughly 90% of us will be exposed to some sort of event that can cause PTSD or depression, but only 10% will develop the disorder. So if you think of contexts like the emergency room, where large numbers of people come through, or the battlefield, where large numbers of people are exposed to potentially traumatic events, or even post terrorist attack events, it’s very hard to know who needs the resources and what would help them. So if you have algorithms to detect people at risk, you can much more efficiently give resources to those who are most in need.
There’s a large literature showing that if you intervene with people who don’t need help, who are going to be resilient, you can actually increase the probability of them developing PTSD. So to have effective treatment, you really have to know who needs the treatment, you need methods to identify those at risk, and you need methods to identify what are the risk factors that are driving that individual to develop the disorder.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Bias Reduction, Better Access Key to COVID-19 Equity Gains
April 14th 2025Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Read More
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More